Proton Pump Inhibitors and Cancer Risk: A Comprehensive Review of Epidemiological and Mechanistic Evidence
Conclusions: Despite the well-established cancer risk associated with PPIs, it is notable that these medications continue to be widely prescribed for periods longer than 3 months. Thus, it is of paramount importance for clinicians and patients to thoughtfully evaluate the potential risks and benefits of long-term PPI usage and explore alternative treatments before making informed decisions regarding their medical management.PMID:38610738 | DOI:10.3390/jcm13071970
Source: Clinical Colorectal Cancer - Category: Cancer & Oncology Authors: Ibrahim O Sawaid Abraham O Samson Source Type: research
More News: Acid Reflux | Cancer | Cancer & Oncology | Colorectal Cancer | Epidemiology | Esomeprazole | Esophagus Cancer | Famotidine | Gastric (Stomach) Cancer | Gastroenterology | Gastroesophageal Reflux Disease | GERD | Lansoprazole | Nexium | Omeprazole | Pancreas | Pancreatic Cancer | Pantoprazole | Peptic Ulcer | Prevacid | Prilosec | Proton Pump Inhibitors PPIs | Protonix | Study | Toxicology | Vitamins